STOCK TITAN

Director Robert Canarick awarded 50,000 INTEGRATED BIOPHARMA (INBP) stock options

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

INTEGRATED BIOPHARMA director Robert Canarick received a grant of 50,000 stock options for common stock. The options have an exercise price of $0.19 per share and expire on June 24, 2036. They vest in four equal installments of 12,500 options between September 2026 and June 2027.

Positive

  • None.

Negative

  • None.
Insider Canarick Robert
Role null
Type Security Shares Price Value
Grant/Award Stock Option (Right to Buy) 50,000 $0.00 --
Holdings After Transaction: Stock Option (Right to Buy) — 50,000 shares (Direct, null)
Footnotes (1)
  1. [object Object]
Option grant size 50,000 options Stock Option (Right to Buy) grant to director
Exercise price $0.19 per share Conversion or exercise price of options
Options after grant 50,000 options Total derivative securities following transaction
Vesting installment size 12,500 options Each of four vesting dates from 2026 to 2027
Option expiration date June 24, 2036 Expiration of stock option grant
Stock Option (Right to Buy) financial
"Security title is described as "Stock Option (Right to Buy)"."
exercise price financial
"Conversion or exercise price is reported as $0.1900 per share."
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vesting financial
"The stock options vest and become exercisable in four equal installments."
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
expiration date financial
"The options carry an expiration date of June 24, 2036."
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Canarick Robert

(Last)(First)(Middle)
C/O INTEGRATED BIOPHARMA, INC.
225 LONG AVENUE, BLDG 15

(Street)
HILLSIDE NEW JERSEY 07205

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
INTEGRATED BIOPHARMA INC [ INBP ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/24/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy)$0.1906/24/2026A50,000 (1)06/24/2036Common Stock50,000$050,000D
Explanation of Responses:
1. The stock options vest and become exercisable in four equal installments (12,500 stock options each) on each of September 30, 2026, December 31, 2026, March 31, 2027 and June 30, 2027.
/s/ Robert Canarick06/25/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did INBP director Robert Canarick report on this Form 4?

Robert Canarick reported receiving a grant of 50,000 stock options for INTEGRATED BIOPHARMA common stock. These options were awarded as compensation, not purchased on the open market, and represent a new derivative position tied to future potential share ownership.

What is the exercise price of Robert Canarick’s INBP stock options?

The granted stock options have an exercise price of $0.19 per share. This is the fixed price at which Canarick can buy INTEGRATED BIOPHARMA common stock if he chooses to exercise the options before expiration.

When do Robert Canarick’s 50,000 INBP stock options vest?

The 50,000 stock options vest in four equal installments of 12,500 options each. Vesting dates are September 30, 2026, December 31, 2026, March 31, 2027, and June 30, 2027, aligning the award with multi-year service to the company.

When do the newly granted INBP stock options held by Robert Canarick expire?

The stock options granted to Robert Canarick expire on June 24, 2036. After that expiration date, any unexercised options will lapse, and he will no longer have the right to buy INTEGRATED BIOPHARMA shares at the $0.19 exercise price.

How many INBP options does Robert Canarick hold after this Form 4 transaction?

Following this grant, Robert Canarick holds 50,000 stock options according to the filing. These options are subject to the disclosed vesting schedule and provide potential future rights to acquire INTEGRATED BIOPHARMA common stock at $0.19 per share.